Cite
HARVARD Citation
O'Day, K. et al. (2015). Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden. Journal of medical economics. pp. 295-302. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
O'Day, K. et al. (2015). Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden. Journal of medical economics. pp. 295-302. [Online].